Table 4.
Studies reporting risk factors for bleeding in MPN
| Risk factors | Wehmeier et al.1 (included ET, PV, PMF and CML) [7] | Kaife et al.2 (included PV, ET, PMF, MPN-U, post-ET-MF and post-PV-MF) [19] | Kander et al.1 (included PV, ET, PMF, MP PV, ET, PMF, MPN-U, post-ET-MF, post-PV-MF and MDS/MPN) [9] | Finazzi et al.1 (included ET and prefibrotic MF) [11] |
|---|---|---|---|---|
| Age at diagnosis | − | NR | + | − |
| Thrombocytopenia | − | NR | NR | NR |
| Thrombocytosis | − | − | NR | − |
| JAK 2 positivity | NR | NR | − | − |
| Aspirin use | NR | − | − | + |
| Anticoagulation | NR | −VKA and Rivaroxaban + Heparin | NR | NR |
| Thrombotic/thromboembolic event in medical history | NR | + | − | − |
| Palpable splenomegaly | NR | + | NR | − |
| MPN subtype | NR | NR | − | + (prefibrotic MF>ET) |
| Leukocytosis (WBC=or> 11K) | NR | NR | NR | + |
| History of bleeding | NR | NR | NR | + |
| Decreased RBC number | + | NR | NR | NR |
| Decreased Hemoglobin | + | NR | NR | NR |
| Decreased percentage of segmented neutrophils | + | NR | NR | NR |
+ denotes significant association, − denotes no significant association. NR = not reported.
1
denotes multivariate analysis,
2
denotes univariate analysis.